New facility provides additional working capital to continue Company market expansion plans BELGRADE, Mont. , May 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international

BELGRADE, Mont. , May 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc. , a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that its Chief

BELGRADE, Mont. , May 13, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, has established a record date for its 2016 annual meeting of stockholders.

BELGRADE, Mont. , May 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced FDA clearance for the posterior cervical screw indication on the Certex® Spinal Fixation System.

See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to core pro forma recurring revenue of $19.2 million in first quarter 2015 Gross profit increased slightly

BELGRADE, Mont. , April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended March 31st, 2016 , at the close of

BELGRADE, Mont. , April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the awarding of two grants from the Montana Department of Commerce totaling $155,000 to aid Bacterin

Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3 million BELGRADE, Mont. , April 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc.

BELGRADE, Mont. , March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, received FDA clearance of the Xspan™ Laminoplasty

BELGRADE, Mont. , March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its biologics portfolio through a distribution relationship with Vivex Biomedical, Inc.